Subtle differences between the Pfizer Inc.-BioNTech SE and Moderna Inc. vaccines are emerging across patient groups over time, but what this all means in the real world is still unclear.
The congressional inquiry adds to pressure on the U.S. agency charged with regulating products that account for one-fifth of consumer spending.
Moderna’s COVID-19 vaccine generated more than double the antibodies of a similar shot made by Pfizer and BioNTech in research that compared immune responses evoked by the two inoculations.
The New England Journal of Medicine opinion piece is another sign of persistent furor over the agency’s decision.
Around the globe, people and governments are finding out that COVID-19 won’t be thrashed into extinction, but is more likely to enter a long, endemic tail.
The company plans to apply for regulatory clearance globally, with much of the first available doses going to low- and middle-income countries.
The approval appears to signal a fundamental shift in the way the FDA thinks about Alzheimer's disease, which could have lasting ramifications for other drugs in the pipeline.
Health officials are exploring whether and how an immune reaction may occur in people who have received vaccines made by AstraZeneca and Johnson & Johnson.
Mutations that likely confer partial resistance to vaccines and antibody treatments are now prevalent in both South Africa and Brazil, and they are threatening to spread worldwide.
Pfizer Inc. scaled back its COVID-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.
